People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adagio Therapeutics, Inc. | — | Biotechnology | Series D+ | $489.1M | $446.7M | 2022 |
| Fractyl Laboratories Inc. | — | Other Health Care | Series C | $290.1M | $309.8M | 2021 |
Marc Elia at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Elia on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hemant Taneja | 1 | 21 |
| Ajay Royan | 1 | 13 |
| Amy Schulman | 1 | 11 |
| Terry McGuire | 1 | 8 |
| Brian Dovey | 1 | 7 |
| TERRANCE G. MCGUIRE | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Stanley Lapidus | 1 | 7 |
| Tillman U. Gerngross | 1 | 5 |
| Diane Marcou | 1 | 5 |
| William Bradley | 1 | 4 |
| CHRISTOPHER GABRIELI | 1 | 3 |
| Allan Will | 1 | 3 |
| Terrance U McGuire | 1 | 2 |
| MICHAEL HUANG | 1 | 2 |
| Michael S. Wyzga | 1 | 2 |
| NIMESH SHAH | 1 | 2 |
| Clive A. Meanwell | 1 | 2 |
| KELLY BARNES | 1 | 2 |
| JOHN AMATRUDA | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.